{"transactions":[{"id":1842550,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-28T22:12:57.000Z","date":"2023-06-27","kind":"sale","planned":false,"acquired":false,"shares":937404,"price":0.5194,"value":486887.6376,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4976 to $0.5985, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities of the Issuer are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":731458,"source":{"system":"sec-edgar","filing":"0000899243-23-016659","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924323016659/doc4.xml","form_type":"4"}},{"id":1842549,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-28T22:12:57.000Z","date":"2023-06-26","kind":"sale","planned":false,"acquired":false,"shares":2746138,"price":0.6125,"value":1682009.525,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.50 to $0.7801, inclusive. The Reporting Person undertakes to provide to Avalo Therapeutics, Inc. (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and footnote 3."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities of the Issuer are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1668862,"source":{"system":"sec-edgar","filing":"0000899243-23-016659","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924323016659/doc4.xml","form_type":"4"}},{"id":2024388,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2023-02-09T21:32:03.000Z","date":"2023-02-07","kind":"purchase","acquired":true,"shares":450000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares are directly owned by Mr. Boyd in his personal capacity."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amount reflects the effect of the 1-for-12 reverse stock split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":450000,"derivative":{"exercise_price":5,"exercise_date":"2023-02-07","expiration_date":"2024-02-07","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0000899243-23-004412","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924323004412/doc4.xml","form_type":"4"}},{"id":2024387,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-09T21:32:03.000Z","date":"2023-02-07","kind":"purchase","acquired":true,"shares":450000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of common stock and accompanying warrant were purchased together for $3.98.  The warrants are subject to a 4.99% beneficial ownership limitation on exercise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amount reflects the effect of the 1-for-12 reverse stock split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4415000,"source":{"system":"sec-edgar","filing":"0000899243-23-004412","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924323004412/doc4.xml","form_type":"4"}},{"id":2024386,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-09T21:32:03.000Z","date":"2023-02-03","kind":"other","acquired":true,"shares":334,"price":3.95,"value":1319.3,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amount reflects the effect of the 1-for-12 reverse stock split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3965000,"source":{"system":"sec-edgar","filing":"0000899243-23-004412","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924323004412/doc4.xml","form_type":"4"}},{"id":2265015,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":10596027,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"kind","element":"transactionCoding","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":10596027,"derivative":{"exercise_price":0.63,"underlying":"Common Stock","underlying_shares":10596027},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265014,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":10596027,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"kind","element":"transactionCoding","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":10596027,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":10596027},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265013,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":2072538,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the outstanding shares of the Issuer's common stock (collectively, the \"Shares\") following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2072538,"derivative":{"exercise_price":0.63,"exercise_date":"2018-12-11","expiration_date":"2025-12-11","underlying":"Common Stock","underlying_shares":2072538},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265012,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"disposition_to_issuer","acquired":false,"shares":2072538,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the outstanding shares of the Issuer's common stock (collectively, the \"Shares\") following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":1.93,"exercise_date":"2018-12-11","expiration_date":"2020-12-11","underlying":"Common Stock","underlying_shares":2072538},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265011,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":2360313,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the outstanding shares of the Issuer's common stock (collectively, the \"Shares\") following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2360313,"derivative":{"exercise_price":0.63,"exercise_date":"2020-03-13","expiration_date":"2027-09-15","underlying":"Common Stock","underlying_shares":2360313},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265010,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"disposition_to_issuer","acquired":false,"shares":2360313,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the outstanding shares of the Issuer's common stock (collectively, the \"Shares\") following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":1.04,"exercise_date":"2020-03-13","expiration_date":"2025-09-15","underlying":"Common Stock","underlying_shares":2360313},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265009,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":4607692,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 19.99% beneficial owner of the Shares following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4607692,"derivative":{"exercise_price":0.903,"exercise_date":"2020-07-08","expiration_date":"2028-01-08","underlying":"Common Stock","underlying_shares":4607692},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265008,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"disposition_to_issuer","acquired":false,"shares":4607692,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 19.99% beneficial owner of the Shares following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":0.903,"exercise_date":"2020-07-08","expiration_date":"2026-01-08","underlying":"Common Stock","underlying_shares":4607692},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265007,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":3175924,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 19.99% beneficial owner of the Shares following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3175924,"derivative":{"exercise_price":0.903,"exercise_date":"2020-07-08","expiration_date":"2028-01-08","underlying":"Common Stock","underlying_shares":3175924},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265006,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"disposition_to_issuer","acquired":false,"shares":3175924,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 19.99% beneficial owner of the Shares following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":0.903,"exercise_date":"2020-07-08","expiration_date":"2026-01-08","underlying":"Common Stock","underlying_shares":3175924},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265005,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":4773269,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the outstanding shares of the Issuer's common stock (collectively, the \"Shares\") following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4773269,"derivative":{"exercise_price":0.63,"exercise_date":"2021-07-08","expiration_date":"2029-01-08","underlying":"Common Stock","underlying_shares":4773269},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265004,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"disposition_to_issuer","acquired":false,"shares":4773269,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the outstanding shares of the Issuer's common stock (collectively, the \"Shares\") following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":1.97,"exercise_date":"2021-07-08","expiration_date":"2027-01-08","underlying":"Common Stock","underlying_shares":4773269},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2334989,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-14T21:38:41.000Z","date":"2022-03-14","kind":"purchase","acquired":true,"shares":100000,"price":0.6494,"value":64940.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":47576000,"source":{"system":"sec-edgar","filing":"0000899243-22-010904","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322010904/doc4.xml","form_type":"4"}},{"id":2334988,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-14T21:38:41.000Z","date":"2022-03-11","kind":"purchase","acquired":true,"shares":100000,"price":0.6878,"value":68780.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":47476000,"source":{"system":"sec-edgar","filing":"0000899243-22-010904","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322010904/doc4.xml","form_type":"4"}},{"id":2334987,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-14T21:38:41.000Z","date":"2022-03-10","kind":"purchase","acquired":true,"shares":26000,"price":0.701,"value":18226.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":47376000,"source":{"system":"sec-edgar","filing":"0000899243-22-010904","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322010904/doc4.xml","form_type":"4"}},{"id":2347212,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-07T23:09:15.000Z","date":"2022-03-07","kind":"purchase","acquired":true,"shares":325000,"price":0.6564,"value":213330.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6298 to $0.6933, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":47350000,"source":{"system":"sec-edgar","filing":"0000899243-22-009744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322009744/doc4.xml","form_type":"4"}},{"id":2347211,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-07T23:09:15.000Z","date":"2022-03-04","kind":"purchase","acquired":true,"shares":135000,"price":0.7045,"value":95107.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7020 to $0.7082, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":47025000,"source":{"system":"sec-edgar","filing":"0000899243-22-009744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322009744/doc4.xml","form_type":"4"}},{"id":2347210,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-07T23:09:15.000Z","date":"2022-03-03","kind":"purchase","acquired":true,"shares":50000,"price":0.7139,"value":35695.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":46890000,"source":{"system":"sec-edgar","filing":"0000899243-22-009744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322009744/doc4.xml","form_type":"4"}},{"id":2368414,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-28T22:53:01.000Z","date":"2022-02-25","kind":"purchase","acquired":true,"shares":40000,"price":0.7929,"value":31716.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7877 to $0.7997, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":46840000,"source":{"system":"sec-edgar","filing":"0000899243-22-008145","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322008145/doc4.xml","form_type":"4"}},{"id":2368413,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-28T22:53:01.000Z","date":"2022-02-24","kind":"purchase","acquired":true,"shares":100000,"price":0.8009,"value":80090.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7803 to $0.8163, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":46800000,"source":{"system":"sec-edgar","filing":"0000899243-22-008145","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322008145/doc4.xml","form_type":"4"}},{"id":2381641,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-22T23:37:32.000Z","date":"2022-02-22","kind":"purchase","acquired":true,"shares":83000,"price":0.772,"value":64076.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7538 to $0.8086, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":46700000,"source":{"system":"sec-edgar","filing":"0000899243-22-007249","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322007249/doc4.xml","form_type":"4"}},{"id":2381640,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-22T23:37:32.000Z","date":"2022-02-18","kind":"purchase","acquired":true,"shares":55000,"price":0.8225,"value":45237.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8145 to $0.8293, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":46617000,"source":{"system":"sec-edgar","filing":"0000899243-22-007249","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322007249/doc4.xml","form_type":"4"}},{"id":2381639,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-22T23:37:32.000Z","date":"2022-02-17","kind":"purchase","acquired":true,"shares":150000,"price":0.815,"value":122250.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8119 to $0.8357, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":46562000,"source":{"system":"sec-edgar","filing":"0000899243-22-007249","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322007249/doc4.xml","form_type":"4"}},{"id":2429893,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-20T23:14:50.000Z","date":"2022-01-20","kind":"purchase","acquired":true,"shares":12000,"price":0.8507,"value":10208.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":46412000,"source":{"system":"sec-edgar","filing":"0000899243-22-002693","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322002693/doc4.xml","form_type":"4"}},{"id":2429892,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-20T23:14:50.000Z","date":"2022-01-19","kind":"purchase","acquired":true,"shares":93700,"price":0.8757,"value":82053.09,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8501 to $0.8956, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":46400000,"source":{"system":"sec-edgar","filing":"0000899243-22-002693","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322002693/doc4.xml","form_type":"4"}},{"id":2429891,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-20T23:14:50.000Z","date":"2022-01-18","kind":"purchase","acquired":true,"shares":206300,"price":0.8833,"value":182224.79,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8762 to $0.9029, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":46306300,"source":{"system":"sec-edgar","filing":"0000899243-22-002693","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322002693/doc4.xml","form_type":"4"}},{"id":2434645,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-14T22:49:32.000Z","date":"2022-01-14","kind":"purchase","acquired":true,"shares":85000,"price":0.9291,"value":78973.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9137 to $0.9497, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":46100000,"source":{"system":"sec-edgar","filing":"0000899243-22-002025","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322002025/doc4.xml","form_type":"4"}},{"id":2434644,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-14T22:49:32.000Z","date":"2022-01-13","kind":"purchase","acquired":true,"shares":312700,"price":1.0042,"value":314013.34,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":46015000,"source":{"system":"sec-edgar","filing":"0000899243-22-002025","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322002025/doc4.xml","form_type":"4"}},{"id":2434643,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-14T22:49:32.000Z","date":"2022-01-12","kind":"purchase","acquired":true,"shares":57300,"price":1.0433,"value":59781.09,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.0300 to $1.0550, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":45702300,"source":{"system":"sec-edgar","filing":"0000899243-22-002025","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322002025/doc4.xml","form_type":"4"}},{"id":2437467,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T23:18:29.000Z","date":"2022-01-11","kind":"purchase","acquired":true,"shares":16003,"price":0.9587,"value":15342.0761,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9484 to $0.9795, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":45645000,"source":{"system":"sec-edgar","filing":"0000899243-22-001618","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322001618/doc4.xml","form_type":"4"}},{"id":2437466,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T23:18:29.000Z","date":"2022-01-10","kind":"purchase","acquired":true,"shares":491097,"price":0.9868,"value":484614.5196,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9733 to $1.0064, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":45628997,"source":{"system":"sec-edgar","filing":"0000899243-22-001618","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322001618/doc4.xml","form_type":"4"}},{"id":2437465,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T23:18:29.000Z","date":"2022-01-07","kind":"purchase","acquired":true,"shares":137900,"price":1.0368,"value":142974.72,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.0097 to $1.0811, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":45137900,"source":{"system":"sec-edgar","filing":"0000899243-22-001618","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322001618/doc4.xml","form_type":"4"}},{"id":2565179,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-17T18:25:07.000Z","date":"2021-09-17","kind":"purchase","acquired":true,"shares":5454545,"price":2.2,"value":11999999.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (f/k/a Cerecor Inc.) (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":45000000,"source":{"system":"sec-edgar","filing":"0000899243-21-036402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924321036402/doc4.xml","form_type":"4"}},{"id":2565178,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-17T18:25:07.000Z","date":"2021-09-16","kind":"purchase","acquired":true,"shares":150000,"price":2.2797,"value":341955.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $2.1874 to $2.3089, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (f/k/a Cerecor Inc.) (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":39545455,"source":{"system":"sec-edgar","filing":"0000899243-21-036402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924321036402/doc4.xml","form_type":"4"}},{"id":2565177,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-17T18:25:07.000Z","date":"2021-09-15","kind":"purchase","acquired":true,"shares":95455,"price":2.2623,"value":215947.8465,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $2.1461 to $2.3594, inclusive.  The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (f/k/a Cerecor Inc.) (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":39395455,"source":{"system":"sec-edgar","filing":"0000899243-21-036402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924321036402/doc4.xml","form_type":"4"}},{"id":2597386,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-18T21:54:48.000Z","date":"2021-08-18","kind":"purchase","acquired":true,"shares":20000,"price":2.7775,"value":55550.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Cerecor Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":39300000,"source":{"system":"sec-edgar","filing":"0000899243-21-033505","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924321033505/doc4.xml","form_type":"4"}},{"id":2597385,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-18T21:54:48.000Z","date":"2021-08-16","kind":"purchase","acquired":true,"shares":30000,"price":2.7546,"value":82638.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $2.7507 to $2.774, inclusive.  The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Cerecor Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":39280000,"source":{"system":"sec-edgar","filing":"0000899243-21-033505","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924321033505/doc4.xml","form_type":"4"}},{"id":2611173,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-06T19:15:57.000Z","date":"2021-08-06","kind":"purchase","acquired":true,"shares":25000,"price":2.8252,"value":70630.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities (the \"Shares\") of Cerecor Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":39250000,"source":{"system":"sec-edgar","filing":"0001567619-21-014631","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000156761921014631/doc1.xml","form_type":"4"}},{"id":2611172,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-06T19:15:57.000Z","date":"2021-08-05","kind":"purchase","acquired":true,"shares":25000,"price":2.7718,"value":69295.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities (the \"Shares\") of Cerecor Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":39225000,"source":{"system":"sec-edgar","filing":"0001567619-21-014631","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000156761921014631/doc1.xml","form_type":"4"}},{"id":2611171,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-06T19:15:57.000Z","date":"2021-08-04","kind":"purchase","acquired":true,"shares":100000,"price":2.6859,"value":268590.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.6541 to $2.6997, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities (the \"Shares\") of Cerecor Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":39200000,"source":{"system":"sec-edgar","filing":"0001567619-21-014631","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000156761921014631/doc1.xml","form_type":"4"}},{"id":2617060,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-03T21:09:33.000Z","date":"2021-08-02","kind":"sale","acquired":false,"shares":192775,"price":2.402,"value":463045.55,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $2.3595 to $2.5144, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":785000,"source":{"system":"sec-edgar","filing":"0001567619-21-014361","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000156761921014361/doc1.xml","form_type":"4"}},{"id":2617059,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-03T21:09:33.000Z","date":"2021-07-30","kind":"sale","acquired":false,"shares":68188,"price":2.692,"value":183562.096,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $2.6145\t to $2.7604, inclusive.  The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":977775,"source":{"system":"sec-edgar","filing":"0001567619-21-014361","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000156761921014361/doc1.xml","form_type":"4"}},{"id":2621983,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2021-07-29T23:59:52.000Z","date":"2021-07-27","kind":"exercise","acquired":false,"shares":4092,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series C Convertible Preferred Stock has no expiration date and was convertible at any time at the option of the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":4.8,"exercise_date":"2018-04-17","underlying":"Common Stock","underlying_shares":852500},"source":{"system":"sec-edgar","filing":"0000899243-21-030722","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000089924321030722/doc4.xml","form_type":"4"}},{"id":2621982,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-29T23:59:52.000Z","date":"2021-07-29","kind":"sale","acquired":false,"shares":400000,"price":3,"value":1200000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $2.85 to $3.24, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1045963,"source":{"system":"sec-edgar","filing":"0000899243-21-030722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000089924321030722/doc4.xml","form_type":"4"}},{"id":2621981,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-29T23:59:52.000Z","date":"2021-07-28","kind":"sale","acquired":false,"shares":375443,"price":3.2831,"value":1232616.9133,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $3.1713 to $3.4093, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1445963,"source":{"system":"sec-edgar","filing":"0000899243-21-030722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000089924321030722/doc4.xml","form_type":"4"}},{"id":2621980,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-29T23:59:52.000Z","date":"2021-07-27","kind":"sale","acquired":false,"shares":581614,"price":3.799,"value":2209551.586,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $3.5852 to $3.9402, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1821406,"source":{"system":"sec-edgar","filing":"0000899243-21-030722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000089924321030722/doc4.xml","form_type":"4"}},{"id":2621979,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-29T23:59:52.000Z","date":"2021-07-27","kind":"sale","acquired":false,"shares":532069,"price":4.5877,"value":2440972.9513,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $4.0011 to $4.9908, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2403020,"source":{"system":"sec-edgar","filing":"0000899243-21-030722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000089924321030722/doc4.xml","form_type":"4"}},{"id":2621978,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-29T23:59:52.000Z","date":"2021-07-27","kind":"sale","acquired":false,"shares":729114,"price":5.4397,"value":3966161.4258,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $5.1066 to $5.9464, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2935089,"source":{"system":"sec-edgar","filing":"0000899243-21-030722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000089924321030722/doc4.xml","form_type":"4"}},{"id":2621977,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-29T23:59:52.000Z","date":"2021-07-27","kind":"sale","acquired":false,"shares":461797,"price":6.4549,"value":2980853.4553,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $6.0052 to $6.9970, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3664203,"source":{"system":"sec-edgar","filing":"0000899243-21-030722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000089924321030722/doc4.xml","form_type":"4"}},{"id":2621976,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-29T23:59:52.000Z","date":"2021-07-27","kind":"sale","acquired":false,"shares":73101,"price":7.0602,"value":516107.6802,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $7.002 to $7.1559, inclusive.  The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (6), (7), (8) and (9) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4126000,"source":{"system":"sec-edgar","filing":"0000899243-21-030722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000089924321030722/doc4.xml","form_type":"4"}},{"id":2621975,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-29T23:59:52.000Z","date":"2021-07-27","kind":"exercise","acquired":true,"shares":852500,"price":4.8,"value":4092000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4199101,"source":{"system":"sec-edgar","filing":"0000899243-21-030722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000089924321030722/doc4.xml","form_type":"4"}},{"id":2637597,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2021-07-09T22:03:22.000Z","date":"2021-07-08","kind":"grant","acquired":true,"shares":4773269,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4773269,"derivative":{"exercise_price":1.97,"underlying":"Common Stock","underlying_shares":4773269},"source":{"system":"sec-edgar","filing":"0000899243-21-028023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924321028023/doc4.xml","form_type":"4"}},{"id":2637596,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2021-07-09T22:03:22.000Z","date":"2021-07-08","kind":"grant","acquired":true,"shares":4773269,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4773269,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":4773269},"source":{"system":"sec-edgar","filing":"0000899243-21-028023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924321028023/doc4.xml","form_type":"4"}},{"id":2658494,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2021-06-22T08:33:40.000Z","date":"2021-06-15","kind":"other","acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable and became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities were directly held by the Master Fund. The reported securities may have been deemed to be indirectly beneficially owned by Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund. The reported securities may also have been deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Mr. Boyd disclaim beneficial ownership of the disposed securities except to the extent of their respective former pecuniary interests therein, and this report shall not be deemed an admission that either of them were the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.5,"expiration_date":"2026-01-19","underlying":"Common Stock","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000919574-21-004187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957421004187/ownership.xml","form_type":"4"}},{"id":2658493,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2021-06-22T08:33:40.000Z","date":"2021-06-15","kind":"other","acquired":false,"shares":1000000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable and became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities were directly held by the Master Fund. The reported securities may have been deemed to be indirectly beneficially owned by Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund. The reported securities may also have been deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Mr. Boyd disclaim beneficial ownership of the disposed securities except to the extent of their respective former pecuniary interests therein, and this report shall not be deemed an admission that either of them were the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.5,"expiration_date":"2026-01-19","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000919574-21-004187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957421004187/ownership.xml","form_type":"4"}},{"id":2658492,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2021-06-22T08:33:40.000Z","date":"2021-06-15","kind":"other","acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable and became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities were directly held by the Master Fund. The reported securities may have been deemed to be indirectly beneficially owned by Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund. The reported securities may also have been deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Mr. Boyd disclaim beneficial ownership of the disposed securities except to the extent of their respective former pecuniary interests therein, and this report shall not be deemed an admission that either of them were the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.5,"expiration_date":"2025-12-16","underlying":"Common Stock","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000919574-21-004187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957421004187/ownership.xml","form_type":"4"}},{"id":2658491,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2021-06-22T08:33:40.000Z","date":"2021-06-15","kind":"other","acquired":false,"shares":4000000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable and became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities were directly held by the Master Fund. The reported securities may have been deemed to be indirectly beneficially owned by Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund. The reported securities may also have been deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Mr. Boyd disclaim beneficial ownership of the disposed securities except to the extent of their respective former pecuniary interests therein, and this report shall not be deemed an admission that either of them were the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.5,"expiration_date":"2025-12-16","underlying":"Common Stock","underlying_shares":4000000},"source":{"system":"sec-edgar","filing":"0000919574-21-004187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957421004187/ownership.xml","form_type":"4"}},{"id":2658490,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series G Warrants","published_at":"2021-06-22T08:33:40.000Z","date":"2021-06-15","kind":"other","acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable and became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities were directly held by the Master Fund. The reported securities may have been deemed to be indirectly beneficially owned by Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund. The reported securities may also have been deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Mr. Boyd disclaim beneficial ownership of the disposed securities except to the extent of their respective former pecuniary interests therein, and this report shall not be deemed an admission that either of them were the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.7,"expiration_date":"2025-03-25","underlying":"Common Stock","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000919574-21-004187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957421004187/ownership.xml","form_type":"4"}},{"id":2658489,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series G Warrants","published_at":"2021-06-22T08:33:40.000Z","date":"2021-06-15","kind":"other","acquired":false,"shares":1200000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable and became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities were directly held by the Master Fund. The reported securities may have been deemed to be indirectly beneficially owned by Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund. The reported securities may also have been deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Mr. Boyd disclaim beneficial ownership of the disposed securities except to the extent of their respective former pecuniary interests therein, and this report shall not be deemed an admission that either of them were the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.7,"expiration_date":"2025-03-25","underlying":"Common Stock","underlying_shares":1200000},"source":{"system":"sec-edgar","filing":"0000919574-21-004187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957421004187/ownership.xml","form_type":"4"}},{"id":2658488,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series G Warrants","published_at":"2021-06-22T08:33:40.000Z","date":"2021-06-15","kind":"other","acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable and became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities were directly held by the Master Fund. The reported securities may have been deemed to be indirectly beneficially owned by Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund. The reported securities may also have been deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Mr. Boyd disclaim beneficial ownership of the disposed securities except to the extent of their respective former pecuniary interests therein, and this report shall not be deemed an admission that either of them were the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.25,"expiration_date":"2025-09-14","underlying":"Common Stock","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000919574-21-004187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957421004187/ownership.xml","form_type":"4"}},{"id":2658487,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series G Warrants","published_at":"2021-06-22T08:33:40.000Z","date":"2021-06-15","kind":"other","acquired":false,"shares":1200000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable and became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities were directly held by the Master Fund. The reported securities may have been deemed to be indirectly beneficially owned by Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund. The reported securities may also have been deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Mr. Boyd disclaim beneficial ownership of the disposed securities except to the extent of their respective former pecuniary interests therein, and this report shall not be deemed an admission that either of them were the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.25,"expiration_date":"2025-09-14","underlying":"Common Stock","underlying_shares":1200000},"source":{"system":"sec-edgar","filing":"0000919574-21-004187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957421004187/ownership.xml","form_type":"4"}},{"id":2658486,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Warrants","published_at":"2021-06-22T08:33:40.000Z","date":"2021-06-15","kind":"other","acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable and became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities were directly held by the Master Fund. The reported securities may have been deemed to be indirectly beneficially owned by Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund. The reported securities may also have been deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Mr. Boyd disclaim beneficial ownership of the disposed securities except to the extent of their respective former pecuniary interests therein, and this report shall not be deemed an admission that either of them were the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":0.05,"expiration_date":"2024-11-12","underlying":"Common Stock","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000919574-21-004187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957421004187/ownership.xml","form_type":"4"}},{"id":2658485,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Warrants","published_at":"2021-06-22T08:33:40.000Z","date":"2021-06-15","kind":"other","acquired":false,"shares":2625000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable and became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities were directly held by the Master Fund. The reported securities may have been deemed to be indirectly beneficially owned by Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund. The reported securities may also have been deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Mr. Boyd disclaim beneficial ownership of the disposed securities except to the extent of their respective former pecuniary interests therein, and this report shall not be deemed an admission that either of them were the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":0.05,"expiration_date":"2024-11-12","underlying":"Common Stock","underlying_shares":2625000},"source":{"system":"sec-edgar","filing":"0000919574-21-004187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957421004187/ownership.xml","form_type":"4"}},{"id":2658484,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants","published_at":"2021-06-22T08:33:40.000Z","date":"2021-06-15","kind":"other","acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable and became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities were directly held by the Master Fund. The reported securities may have been deemed to be indirectly beneficially owned by Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund. The reported securities may also have been deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Mr. Boyd disclaim beneficial ownership of the disposed securities except to the extent of their respective former pecuniary interests therein, and this report shall not be deemed an admission that either of them were the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":0.022,"expiration_date":"2024-11-12","underlying":"Common Stock","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000919574-21-004187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957421004187/ownership.xml","form_type":"4"}},{"id":2658483,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants","published_at":"2021-06-22T08:33:40.000Z","date":"2021-06-15","kind":"other","acquired":false,"shares":2625000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable and became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities were directly held by the Master Fund. The reported securities may have been deemed to be indirectly beneficially owned by Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund. The reported securities may also have been deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Mr. Boyd disclaim beneficial ownership of the disposed securities except to the extent of their respective former pecuniary interests therein, and this report shall not be deemed an admission that either of them were the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":0.022,"expiration_date":"2024-11-12","underlying":"Common Stock","underlying_shares":2625000},"source":{"system":"sec-edgar","filing":"0000919574-21-004187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957421004187/ownership.xml","form_type":"4"}},{"id":2658482,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-22T08:33:40.000Z","date":"2021-06-15","kind":"other","acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These reported securities were disposed of pursuant to a merger between the Issuer, Obalon Therapeutics, Inc. (\"Obalon\") and Optimus Merger Sub, a wholly owned subsidiary of Obalon (\"Merger Sub\") that became effective on June 15, 2021 (the \"Merger\"). As a result of the Merger, Obalon was renamed ReShape Lifesciences Inc. (\"Combined Company\") and all of the reported securities were converted into securities of the Combined Company pursuant to the conversion ratio and all other terms contained in the Agreement and Plan of Merger, dated as of January 19, 2021, by and among the Issuer, Obalon, and Merger Sub (incorporated by reference to Exhibit 2.1 the Form 8-K filed by the Issuer with the SEC on June 15, 2021) (the \"Merger Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities were directly held by the Master Fund. The reported securities may have been deemed to be indirectly beneficially owned by Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund. The reported securities may also have been deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Mr. Boyd disclaim beneficial ownership of the disposed securities except to the extent of their respective former pecuniary interests therein, and this report shall not be deemed an admission that either of them were the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000919574-21-004187","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957421004187/ownership.xml","form_type":"4"}},{"id":2658481,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-22T08:33:40.000Z","date":"2021-06-15","kind":"other","acquired":false,"shares":5330277,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These reported securities were disposed of pursuant to a merger between the Issuer, Obalon Therapeutics, Inc. (\"Obalon\") and Optimus Merger Sub, a wholly owned subsidiary of Obalon (\"Merger Sub\") that became effective on June 15, 2021 (the \"Merger\"). As a result of the Merger, Obalon was renamed ReShape Lifesciences Inc. (\"Combined Company\") and all of the reported securities were converted into securities of the Combined Company pursuant to the conversion ratio and all other terms contained in the Agreement and Plan of Merger, dated as of January 19, 2021, by and among the Issuer, Obalon, and Merger Sub (incorporated by reference to Exhibit 2.1 the Form 8-K filed by the Issuer with the SEC on June 15, 2021) (the \"Merger Agreement\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These reported securities were disposed of pursuant to a merger between the Issuer, Obalon Therapeutics, Inc. (\"Obalon\") and Optimus Merger Sub, a wholly owned subsidiary of Obalon (\"Merger Sub\") that became effective on June 15, 2021 (the \"Merger\"). As a result of the Merger, Obalon was renamed ReShape Lifesciences Inc. (\"Combined Company\") and all of the reported securities were converted into securities of the Combined Company pursuant to the conversion ratio and all other terms contained in the Agreement and Plan of Merger, dated as of January 19, 2021, by and among the Issuer, Obalon, and Merger Sub (incorporated by reference to Exhibit 2.1 the Form 8-K filed by the Issuer with the SEC on June 15, 2021) (the \"Merger Agreement\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities were directly held by the Master Fund. The reported securities may have been deemed to be indirectly beneficially owned by Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund. The reported securities may also have been deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Mr. Boyd disclaim beneficial ownership of the disposed securities except to the extent of their respective former pecuniary interests therein, and this report shall not be deemed an admission that either of them were the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000919574-21-004187","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957421004187/ownership.xml","form_type":"4"}},{"id":2707278,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-18T22:15:17.000Z","date":"2021-05-18","kind":"purchase","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities (the \"Shares\") of Cerecor Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":39100000,"source":{"system":"sec-edgar","filing":"0000919574-21-003782","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000091957421003782/ownership.xml","form_type":"4"}},{"id":2707277,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-18T22:15:17.000Z","date":"2021-05-18","kind":"purchase","acquired":true,"shares":22000,"price":2.33,"value":51260.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This constitutes the weighted average purchase price per Share. The prices range from $2.32 to $2.35. The Reporting Persons will provide upon request by the SEC Staff, the issuer or a security holder of the issuer, full information regarding the number of Shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of Cerecor Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":39100000,"source":{"system":"sec-edgar","filing":"0000919574-21-003782","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000091957421003782/ownership.xml","form_type":"4"}},{"id":2707276,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-18T22:15:17.000Z","date":"2021-05-17","kind":"purchase","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities (the \"Shares\") of Cerecor Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":39078000,"source":{"system":"sec-edgar","filing":"0000919574-21-003782","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000091957421003782/ownership.xml","form_type":"4"}},{"id":2707275,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-18T22:15:17.000Z","date":"2021-05-17","kind":"purchase","acquired":true,"shares":30000,"price":2.2,"value":66000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These Shares were purchased in multiple transactions. The purchase price for each transaction was $2.20 per Share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of Cerecor Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":39078000,"source":{"system":"sec-edgar","filing":"0000919574-21-003782","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000091957421003782/ownership.xml","form_type":"4"}},{"id":2707274,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-18T22:15:17.000Z","date":"2021-05-14","kind":"purchase","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities (the \"Shares\") of Cerecor Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":39048000,"source":{"system":"sec-edgar","filing":"0000919574-21-003782","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000091957421003782/ownership.xml","form_type":"4"}},{"id":2707273,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-18T22:15:17.000Z","date":"2021-05-14","kind":"purchase","acquired":true,"shares":128000,"price":2.15,"value":275200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This constitutes the weighted average purchase price per Share. The prices range from $2.12 to $2.20. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff (the \"SEC Staff\"), the issuer or a security holder of the issuer, full information regarding the number of Shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of Cerecor Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":39048000,"source":{"system":"sec-edgar","filing":"0000919574-21-003782","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000091957421003782/ownership.xml","form_type":"4"}},{"id":2720574,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-11T01:25:21.000Z","date":"2021-03-29","kind":"other","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported Shares were acquired by the Master Fund from the Issuer as a result of 300,000 non-transferable contingent value rights (collectively, the \"CVRs\") granted to the Master Fund as a former shareholder of Innovus Pharmaceuticals, Inc (\"Innovus\") upon consummation of the merger between the Issuer and Innovus on February 14, 2020.  The number of Shares received by the Master Fund pursuant to the CVRs was determined by the Issuer through the application of a formula based on the Issuer's achievement of certain revenue and profitability milestones."}],"balance_after":1342378,"source":{"system":"sec-edgar","filing":"0000919574-21-003313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091957421003313/ownership.xml","form_type":"4"}},{"id":2720573,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-11T01:25:21.000Z","date":"2021-03-29","kind":"other","acquired":true,"shares":2085,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported Shares were acquired by the Master Fund from the Issuer as a result of 300,000 non-transferable contingent value rights (collectively, the \"CVRs\") granted to the Master Fund as a former shareholder of Innovus Pharmaceuticals, Inc (\"Innovus\") upon consummation of the merger between the Issuer and Innovus on February 14, 2020.  The number of Shares received by the Master Fund pursuant to the CVRs was determined by the Issuer through the application of a formula based on the Issuer's achievement of certain revenue and profitability milestones."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported Shares were acquired by the Master Fund from the Issuer as a result of 300,000 non-transferable contingent value rights (collectively, the \"CVRs\") granted to the Master Fund as a former shareholder of Innovus Pharmaceuticals, Inc (\"Innovus\") upon consummation of the merger between the Issuer and Innovus on February 14, 2020.  The number of Shares received by the Master Fund pursuant to the CVRs was determined by the Issuer through the application of a formula based on the Issuer's achievement of certain revenue and profitability milestones."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported shares of common stock (the \"Shares\") of Aytu BioPharma, Inc. (the \"Issuer\") are directly held by Armistice s (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":1342378,"source":{"system":"sec-edgar","filing":"0000919574-21-003313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091957421003313/ownership.xml","form_type":"4"}},{"id":2720572,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-11T01:25:21.000Z","date":"2021-03-20","kind":"other","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported Shares were acquired by the Master Fund from the Issuer as a result of 300,000 non-transferable contingent value rights (collectively, the \"CVRs\") granted to the Master Fund as a former shareholder of Innovus Pharmaceuticals, Inc (\"Innovus\") upon consummation of the merger between the Issuer and Innovus on February 14, 2020.  The number of Shares received by the Master Fund pursuant to the CVRs was determined by the Issuer through the application of a formula based on the Issuer's achievement of certain revenue and profitability milestones."}],"balance_after":1340293,"source":{"system":"sec-edgar","filing":"0000919574-21-003313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091957421003313/ownership.xml","form_type":"4"}},{"id":2720571,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-11T01:25:21.000Z","date":"2021-03-20","kind":"other","acquired":true,"shares":6959,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported Shares were acquired by the Master Fund from the Issuer as a result of 300,000 non-transferable contingent value rights (collectively, the \"CVRs\") granted to the Master Fund as a former shareholder of Innovus Pharmaceuticals, Inc (\"Innovus\") upon consummation of the merger between the Issuer and Innovus on February 14, 2020.  The number of Shares received by the Master Fund pursuant to the CVRs was determined by the Issuer through the application of a formula based on the Issuer's achievement of certain revenue and profitability milestones."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported Shares were acquired by the Master Fund from the Issuer as a result of 300,000 non-transferable contingent value rights (collectively, the \"CVRs\") granted to the Master Fund as a former shareholder of Innovus Pharmaceuticals, Inc (\"Innovus\") upon consummation of the merger between the Issuer and Innovus on February 14, 2020.  The number of Shares received by the Master Fund pursuant to the CVRs was determined by the Issuer through the application of a formula based on the Issuer's achievement of certain revenue and profitability milestones."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported shares of common stock (the \"Shares\") of Aytu BioPharma, Inc. (the \"Issuer\") are directly held by Armistice s (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":1340293,"source":{"system":"sec-edgar","filing":"0000919574-21-003313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091957421003313/ownership.xml","form_type":"4"}},{"id":2744799,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK","published_at":"2021-04-19T20:38:06.000Z","date":"2021-04-15","kind":"exercise","acquired":false,"shares":0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to a conversion election, the reported securities were converted by the Reporting Persons on April 15, 2021 into shares of the Issuer's Common Stock, $0.001 par value. This transaction is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-6(b) promulgated under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a conversion election, the reported securities were converted by the Reporting Persons on April 15, 2021 into shares of the Issuer's Common Stock, $0.001 par value. This transaction is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-6(b) promulgated under the Exchange Act."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of the Issuer's Series B Non-Voting Convertible Preferred Stock do not have an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are directly owned by Mr. Boyd in his personal capacity."}],"balance_after":0,"derivative":{"exercise_price":2,"exercise_date":"2020-01-22","underlying":"COMMON STOCK","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000919574-21-003033","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000091957421003033/ownership.xml","form_type":"4"}},{"id":2744798,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK","published_at":"2021-04-19T20:38:06.000Z","date":"2021-04-15","kind":"exercise","acquired":false,"shares":1257143,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to a conversion election, the reported securities were converted by the Reporting Persons on April 15, 2021 into shares of the Issuer's Common Stock, $0.001 par value. This transaction is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-6(b) promulgated under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a conversion election, the reported securities were converted by the Reporting Persons on April 15, 2021 into shares of the Issuer's Common Stock, $0.001 par value. This transaction is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-6(b) promulgated under the Exchange Act."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of the Issuer's Series B Non-Voting Convertible Preferred Stock do not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities of Cerecor Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":2,"exercise_date":"2020-01-22","underlying":"COMMON STOCK","underlying_shares":6285715},"source":{"system":"sec-edgar","filing":"0000919574-21-003033","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000091957421003033/ownership.xml","form_type":"4"}},{"id":2744797,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-19T20:38:06.000Z","date":"2021-04-15","kind":"exercise","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to a conversion election, the reported securities were converted by the Reporting Persons on April 15, 2021 into shares of the Issuer's Common Stock, $0.001 par value. This transaction is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-6(b) promulgated under the Exchange Act."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Cerecor Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":38920000,"source":{"system":"sec-edgar","filing":"0000919574-21-003033","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000091957421003033/ownership.xml","form_type":"4"}},{"id":2744796,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-19T20:38:06.000Z","date":"2021-04-15","kind":"exercise","acquired":true,"shares":6285715,"price":2,"value":12571430.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to a conversion election, the reported securities were converted by the Reporting Persons on April 15, 2021 into shares of the Issuer's Common Stock, $0.001 par value. This transaction is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-6(b) promulgated under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a conversion election, the reported securities were converted by the Reporting Persons on April 15, 2021 into shares of the Issuer's Common Stock, $0.001 par value. This transaction is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-6(b) promulgated under the Exchange Act."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities of Cerecor Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":38920000,"source":{"system":"sec-edgar","filing":"0000919574-21-003033","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000091957421003033/ownership.xml","form_type":"4"}},{"id":2909288,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-12T22:22:55.000Z","date":"2021-01-08","kind":"purchase","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"balance_after":32634285,"source":{"system":"sec-edgar","filing":"0000919574-21-000248","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000091957421000248/ownership.xml","form_type":"4"}},{"id":2909287,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-12T22:22:55.000Z","date":"2021-01-08","kind":"purchase","acquired":true,"shares":2500000,"price":2.6,"value":6500000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities of Cerecor Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":32634285,"source":{"system":"sec-edgar","filing":"0000919574-21-000248","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000091957421000248/ownership.xml","form_type":"4"}},{"id":2911995,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2021-01-09T01:31:40.000Z","date":"2021-01-06","kind":"purchase","acquired":true,"shares":0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On January 5, 2021, the Issuer and the Master Fund entered into a securities purchase agreement (the \"Securities Purchase Agreement\") pursuant to which the Master Fund acquired from the Issuer in a private placement on the January 6, 2021 closing date: (i) 1,531,101 shares of the Issuer's common stock, $0.01 par value (collectively, the \"Shares\"); and (ii) warrants to purchase up to 1,531,101 Shares with an exercise price of $5.225 per Share (collectively, the \"Warrants\"). The aggregate subscription amount paid by the Master Fund for the Shares and Warrants acquired by it pursuant to the Securities Purchase Agreement was $8,000,002.73."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On January 5, 2021, the Issuer and the Master Fund entered into a securities purchase agreement (the \"Securities Purchase Agreement\") pursuant to which the Master Fund acquired from the Issuer in a private placement on the January 6, 2021 closing date: (i) 1,531,101 shares of the Issuer's common stock, $0.01 par value (collectively, the \"Shares\"); and (ii) warrants to purchase up to 1,531,101 Shares with an exercise price of $5.225 per Share (collectively, the \"Warrants\"). The aggregate subscription amount paid by the Master Fund for the Shares and Warrants acquired by it pursuant to the Securities Purchase Agreement was $8,000,002.73."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"(Continued from Footnote 1) Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1531101,"derivative":{"exercise_price":5.225,"exercise_date":"2021-07-06","expiration_date":"2025-01-06","underlying":"Common Stock","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000919574-21-000168","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000091957421000168/ownership.xml","form_type":"4"}},{"id":2911994,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2021-01-09T01:31:40.000Z","date":"2021-01-06","kind":"purchase","acquired":true,"shares":1531101,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On January 5, 2021, the Issuer and the Master Fund entered into a securities purchase agreement (the \"Securities Purchase Agreement\") pursuant to which the Master Fund acquired from the Issuer in a private placement on the January 6, 2021 closing date: (i) 1,531,101 shares of the Issuer's common stock, $0.01 par value (collectively, the \"Shares\"); and (ii) warrants to purchase up to 1,531,101 Shares with an exercise price of $5.225 per Share (collectively, the \"Warrants\"). The aggregate subscription amount paid by the Master Fund for the Shares and Warrants acquired by it pursuant to the Securities Purchase Agreement was $8,000,002.73."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On January 5, 2021, the Issuer and the Master Fund entered into a securities purchase agreement (the \"Securities Purchase Agreement\") pursuant to which the Master Fund acquired from the Issuer in a private placement on the January 6, 2021 closing date: (i) 1,531,101 shares of the Issuer's common stock, $0.01 par value (collectively, the \"Shares\"); and (ii) warrants to purchase up to 1,531,101 Shares with an exercise price of $5.225 per Share (collectively, the \"Warrants\"). The aggregate subscription amount paid by the Master Fund for the Shares and Warrants acquired by it pursuant to the Securities Purchase Agreement was $8,000,002.73."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"(Continued from Footnote 1) Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1531101,"derivative":{"exercise_price":5.225,"exercise_date":"2021-07-06","expiration_date":"2025-01-06","underlying":"Common Stock","underlying_shares":1531101},"source":{"system":"sec-edgar","filing":"0000919574-21-000168","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000091957421000168/ownership.xml","form_type":"4"}},{"id":2911993,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-09T01:31:40.000Z","date":"2021-01-06","kind":"purchase","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"(Continued from Footnote 1) Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3346601,"source":{"system":"sec-edgar","filing":"0000919574-21-000168","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000091957421000168/ownership.xml","form_type":"4"}},{"id":2911992,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-09T01:31:40.000Z","date":"2021-01-06","kind":"purchase","acquired":true,"shares":1531101,"price":5.225,"value":8000002.725,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On January 5, 2021, the Issuer and the Master Fund entered into a securities purchase agreement (the \"Securities Purchase Agreement\") pursuant to which the Master Fund acquired from the Issuer in a private placement on the January 6, 2021 closing date: (i) 1,531,101 shares of the Issuer's common stock, $0.01 par value (collectively, the \"Shares\"); and (ii) warrants to purchase up to 1,531,101 Shares with an exercise price of $5.225 per Share (collectively, the \"Warrants\"). The aggregate subscription amount paid by the Master Fund for the Shares and Warrants acquired by it pursuant to the Securities Purchase Agreement was $8,000,002.73."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"(Continued from Footnote 1) Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3346601,"source":{"system":"sec-edgar","filing":"0000919574-21-000168","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000091957421000168/ownership.xml","form_type":"4"}},{"id":2944092,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-16T00:17:57.000Z","date":"2020-12-11","kind":"purchase","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"balance_after":1333334,"source":{"system":"sec-edgar","filing":"0000919574-20-007541","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091957420007541/ownership.xml","form_type":"4"}},{"id":2944091,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-16T00:17:57.000Z","date":"2020-12-11","kind":"purchase","acquired":true,"shares":1333334,"price":6,"value":8000004.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities of Aytu BioScience, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1333334,"source":{"system":"sec-edgar","filing":"0000919574-20-007541","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091957420007541/ownership.xml","form_type":"4"}},{"id":2954841,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-07T23:26:28.000Z","date":"2020-12-03","kind":"purchase","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":30134285,"source":{"system":"sec-edgar","filing":"0000919574-20-007449","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000091957420007449/ownership.xml","form_type":"4"}},{"id":2954840,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-07T23:26:28.000Z","date":"2020-12-03","kind":"purchase","acquired":true,"shares":20000,"price":2.44,"value":48800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This constitutes the weighted average purchase price. The prices range from $2.42 to $2.48. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":30134285,"source":{"system":"sec-edgar","filing":"0000919574-20-007449","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000091957420007449/ownership.xml","form_type":"4"}},{"id":2956344,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-04T18:47:44.000Z","date":"2020-12-04","kind":"purchase","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"balance_after":5330277,"source":{"system":"sec-edgar","filing":"0000919574-20-007422","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957420007422/ownership.xml","form_type":"4"}},{"id":2956343,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-04T18:47:44.000Z","date":"2020-12-04","kind":"purchase","acquired":true,"shares":5400,"price":4.13,"value":22302.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This constitutes the weighted average purchase price. The prices range from $3.82 to $4.32. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":5330277,"source":{"system":"sec-edgar","filing":"0000919574-20-007422","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957420007422/ownership.xml","form_type":"4"}},{"id":2956342,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-04T18:47:44.000Z","date":"2020-12-02","kind":"purchase","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"balance_after":5324877,"source":{"system":"sec-edgar","filing":"0000919574-20-007422","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957420007422/ownership.xml","form_type":"4"}},{"id":2956341,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-04T18:47:44.000Z","date":"2020-12-02","kind":"purchase","acquired":true,"shares":1000,"price":4.31,"value":4310.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":5324877,"source":{"system":"sec-edgar","filing":"0000919574-20-007422","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957420007422/ownership.xml","form_type":"4"}}],"next_cursor":"2020-12-04T18:47:44.000000Z,2956341"}